On Tuesday (August 14), CannTrust Holdings (TSX:TRST) reported a 99-percent rise in revenue as part of its second-quarter results for 2018.

Sales for dried cannabis reached just over C$3.5 million for the three-month period, which ended on June 30, compared to a little under C$2 million for the same time period last year. Total revenues for the Canadian licensed producer were C$9 million for the second quarter.


During the quarter, CannTrust’s net selling price per gram lowered from last year to C$8.36.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Eric Paul, CEO of CannTrust, said the company was pleased with its results for the second quarter and is well positioned as a developer of cannabis products for the medical market.

The company revealed its earnings took a hit from C$1.5 million in costs for the ramp up of its Niagara Perpetual Harvest Facility, where expansion construction started in June.

According to the report, the company held a C$11.7-million position in cash as of June 30.

The president of the company, Brad Rogers, added that the operation of the company’s Perpetual Harvest Facility shows the ability for CannTrust to produce high-quality yields and reduced costs.

“Operating a facility of this scale, CannTrust is well-positioned to meet the increased Canadian and global demand for cannabis,” Rogers said.

The 450,000-square-foot hydroponic facility is expected to produce 50,000 kilograms of cannabis per year, before the completion of the 600,000-square-foot expansion. CannTrust estimates the final facility will produce over 100,000 kilograms of cannabis per year.

As part of its quarterly developments, the company highlighted that of the entirety of its cannabis sales, 60 percent represented extracts. The patient count for CannTrust also grew to over 45,000 active consumers of its products.

Investor takeaway

The company holds a “strong buy” rating on the analyst data aggregator site TipRanks, thanks to the reviews from three cannabis analysts.

The most recent report on CannTrust, from Derek Dlay with Canaccord Genuity, gives the company a C$11 share price target. The aggregate price target from TipRanks is C$15.50.

Following an early dip for the stock, shares for CannTrust rose 3.33 percent. The company’s closing price on Tuesday was C$6.83.

The increase for CannTrust represents strong support for its results, as Tuesday’s trading session brought declines across the board in the cannabis space due to Ontario’s decision to delay retail sales of cannabis until April 1, 2019.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less